Analysis of SARS-CoV-2 Emergent variants following AZD7442 (tixagevimab/cilgavimab) for early outpatient treatment of COVID-19 (TACKLE trial)

Analysis of SARS-CoV-2 Emergent variants following AZD7442 (tixagevimab/cilgavimab) for early outpatient treatment of COVID-19 (TACKLE trial)

<p><strong>Introduction:</strong> AZD7442 (tixagevimab/cilgavimab) comprises neutralising monoclonal antibodies (mAbs) that bind to distinct non-overlapping epitopes on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. Viral evolution...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Kijak, GH, Ahani, B, Arbetter, D, Chuecos, F, Gopalakrishnan, V, Beloor, J, Brady, T, Nguyen, A, Roe, TL, Schuko, N, Zhang, T, Hobbs, FDR, Padilla, F, Kelly, EJ, Montgomery, H, Streicher, K
Natura:	Journal article
Lingua:	English
Pubblicazione:	Springer Nature 2023

Documenti analoghi

Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)
di: Gustavo H. Kijak, et al.
Pubblicazione: (2023-11-01)

Outpatient treatment with AZD7442 (tixagevimab/cilgavimab) prevented Covid-19 hospitalizations over 6 months and reduced symptom progression in the TACKLE randomized trial
di: Hobbs, FDR, et al.
Pubblicazione: (2023)

Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial
di: F. D. Richard Hobbs, et al.
Pubblicazione: (2024-02-01)

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial
di: F. D. Richard Hobbs, et al.
Pubblicazione: (2023-09-01)

Serum AZD7442 (tixagevimab–cilgavimab) concentrations and in vitro IC50 values predict SARS‐CoV‐2 neutralising antibody titres
di: Lindsay E Clegg, et al.
Pubblicazione: (2024-01-01)

Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials
di: Myron J. Levin, et al.
Pubblicazione: (2024-05-01)

Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period
di: Samah Hayek, et al.
Pubblicazione: (2025-01-01)

Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients
di: Justin C. Laracy, et al.
Pubblicazione: (2023-06-01)

SARS-CoV-2 pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience
di: Federica Pulvirenti, et al.
Pubblicazione: (2023-10-01)

Evaluation of Neutralizing Capacity of Tixagevimab plus Cilgavimab (AZD7442) against Different SARS-CoV-2 Variants: A Case Report Study with Comparison to a Vaccinated Population
di: Constant Gillot, et al.
Pubblicazione: (2024-01-01)

Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial
di: Montgomery, H, et al.
Pubblicazione: (2022)

Implementation of AZD7442 (Tixagevimab/Cilgavimab) COVID-19 Pre-exposure Prophylaxis (PrEP) in the Largest Health Maintenance Organization in Israel: Real-world Uptake and Sociodemographic and Clinical Characteristics Across Immunocompromised Patient Groups
di: Samah Hayek, et al.
Pubblicazione: (2024-05-01)

Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring
di: Tyler Brady, et al.
Pubblicazione: (2022-10-01)

Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC
di: Ludovic Jondreville, et al.
Pubblicazione: (2022-11-01)

Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy
di: M. V. Zhuravleva, et al.
Pubblicazione: (2023-07-01)

A case of prolonged COVID‐19 treated with tixagevimab/cilgavimab
di: Takahiro Shimizu, et al.
Pubblicazione: (2023-03-01)

Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era.
di: Benjamin Chen, et al.
Pubblicazione: (2023-01-01)

Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era
di: Benjamin Chen, et al.
Pubblicazione: (2023-01-01)

Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections
di: Stefanie Dichtl, et al.
Pubblicazione: (2022-09-01)

Tolerability and outcomes with rollout of tixagevimab-cilgavimab in patients with common variable immunodeficiency
di: Daniela Dluzynski, BS, et al.
Pubblicazione: (2024-08-01)

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi
di: Giulia Zamprogna, et al.
Pubblicazione: (2023-05-01)

P1574: EFFICACY AND SAFETY OF TIXAGEVIMAB AND CILGAVIMAB (EVUSHELD) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
di: Olga Aleshina (Gavrilina), et al.
Pubblicazione: (2023-08-01)

Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?
di: Anna Gidari, et al.
Pubblicazione: (2024-02-01)

Pharmacoeconomic evaluation of the tixagevimab and cilgavimab combination using for pre-exposure prophylaxis of COVID-19
di: Marina V. Zhuravleva, et al.
Pubblicazione: (2023-02-01)

Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies
di: Rachel A. Bender Ignacio, et al.
Pubblicazione: (2025-03-01)

Experience with Tixagevimab and Cilgavimab (Evusheld) in 86 rheumatic patients undergoing anti-B cell therapy with rituximab
di: T. V. Beketova, et al.
Pubblicazione: (2023-04-01)

Real-World Efficacy of COVID-19 Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab in People with Multiple Sclerosis
di: Luke B. Elias, et al.
Pubblicazione: (2023-12-01)

P57 PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA
di: I. Ntanasis-Stathopoulos, et al.
Pubblicazione: (2023-05-01)

Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience
di: Karolina Akinosoglou, et al.
Pubblicazione: (2022-12-01)

Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies
di: Francesco Angotzi, et al.
Pubblicazione: (2023-06-01)

PB2586: PASSIVE PREEXPOSURE IMMUNIZATION BY TIXAGEVIMAB/CILGAVIMAB IN COVID 19 INFECTED HEMATOLOGICAL MALIGNANCY OF EPICOVIDHEA SURVEY
di: Caterina Buquicchio, et al.
Pubblicazione: (2023-08-01)

Effects of Anti-COVID-19 Vaccination and Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab in Kidney and Liver Transplant Recipients
di: Roberta Angelico, et al.
Pubblicazione: (2023-11-01)

Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
di: James Brett Case, et al.
Pubblicazione: (2022-07-01)

Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis
di: Saeed Khorramnia, et al.
Pubblicazione: (2024-06-01)

Real-world clinical outcomes of tixagevimab/cilgavimab in the Omicron outbreak in China: baseline characteristics and interim analysis of the CLEAR study
di: Jianhua You, et al.
Pubblicazione: (2024-10-01)

The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis
di: Shaymaa Glhoom, et al.
Pubblicazione: (2024-01-01)

A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment
di: Daniele Focosi, et al.
Pubblicazione: (2022-09-01)

Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis
di: Saad Alhumaid, et al.
Pubblicazione: (2022-12-01)

Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study
di: Dejan Jakimovski, et al.
Pubblicazione: (2023-02-01)

Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies
di: Anna A. Roppelt, et al.
Pubblicazione: (2023-02-01)